Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Alizapride API Manufacturers & Suppliers
1 verified results
Commercial-scale Suppliers
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Alizapride | CAS No: 59338-93-1 | GMP-certified suppliers
A medication that treats nausea and vomiting, including postoperative cases, by improving gastrointestinal motility and providing antiemetic effects for functional gastrointestinal disorders.
Therapeutic categories
Primary indications
- Alizapride is used in the treatment of nausea and vomiting, including postoperative nausea and vomiting
Product Snapshot
- Alizapride is available in multiple formulation types including injectable solutions, oral tablets, suppositories, and drops
- It is primarily indicated for the management of nausea and vomiting, including postoperative cases
- Currently, Alizapride holds investigational status without finalized regulatory approval
Clinical Overview
The primary mechanism of action of Alizapride involves antagonism of dopamine receptors in the chemoreceptor trigger zone (CTZ) of the central nervous system. This blockade inhibits the activation of emetic pathways triggered by diverse stimuli. Due to structural similarities with metoclopramide, Alizapride demonstrates comparable effects on gastrointestinal motility, supporting its prokinetic properties.
Pharmacodynamically, the drug contributes to modulation of gastrointestinal motility and suppression of nausea through dopamine receptor antagonism. While detailed pharmacokinetic data for Alizapride are limited, typical absorption, distribution, metabolism, and excretion (ADME) characteristics align with dopamine antagonists in its chemical class, suggesting reasonable systemic bioavailability and central nervous system penetration.
Safety considerations for Alizapride include potential extrapyramidal side effects commonly associated with dopamine antagonists. Monitoring for neurological adverse effects such as dystonia or tardive dyskinesia is important during clinical use. Given its investigational status, comprehensive toxicological data are not fully established, necessitating cautious assessment in therapeutic contexts.
Alizapride is categorized among agents targeting alimentary tract disorders, functioning as an antiemetic and prokinetic drug, with implications for gastrointestinal motility disorders. Although it is under investigation and not widely approved globally, its pharmacological profile is relevant for functional gastrointestinal disorder management.
From an API sourcing perspective, procurement should prioritize manufacturers adhering to Good Manufacturing Practice (GMP) standards. Quality control must focus on confirming chemical purity, structural integrity consistent with benzotriazole derivatives, and absence of related impurities. Reliable supply chains and documentation supporting regulatory compliance are essential for use in pharmaceutical formulations.
Identification & chemistry
| Generic name | Alizapride |
|---|---|
| Molecule type | Small molecule |
| CAS | 59338-93-1 |
| UNII | P55703ZRZY |
| DrugBank ID | DB01425 |
Pharmacology
| Summary | Alizapride is a dopamine D2 receptor antagonist that exerts anti-emetic effects by blocking D2 receptors in the central nervous system's chemoreceptor trigger zone. Its pharmacodynamic action inhibits nausea and vomiting triggered by various stimuli. Structurally related to metoclopramide, Alizapride also exhibits prokinetic properties. |
|---|---|
| Mechanism of action | The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)—this action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other atributres related to emesis and prokinetics. |
| Pharmacodynamics | Alizapride is a dopamine antagonist. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Dopamine D2 receptor | Humans | antagonist |
ADME / PK
| Half-life | 3 hours |
|---|---|
| Route of elimination | renal |
Formulation & handling
- Alizapride is a small molecule suitable for multiple administration routes including oral, intramuscular, and intravenous injection.
- Its moderate water solubility and low LogP suggest formulation considerations for achieving adequate bioavailability across dosage forms.
- The solid state and chemical stability typical of benzotriazole derivatives support diverse pharmaceutical formulations such as tablets, suppositories, and injectable solutions.
Regulatory status
Alizapride is a type of Dopamine antagonists
Dopamine antagonists belong to the pharmaceutical API subcategory that plays a crucial role in the management of various medical conditions. These compounds act by blocking dopamine receptors, which are responsible for transmitting signals in the brain. By inhibiting dopamine activity, dopamine antagonists exhibit diverse therapeutic effects.
One significant application of dopamine antagonists is in the treatment of psychiatric disorders. They are commonly used to manage schizophrenia, a severe mental disorder characterized by hallucinations, delusions, and disorganized thinking. Dopamine antagonists help reduce the symptoms of schizophrenia by normalizing the excessive dopamine activity in the brain.
Additionally, these pharmaceutical APIs find application in managing other conditions such as bipolar disorder, nausea, vomiting, and certain movement disorders. Dopamine antagonists can effectively alleviate the symptoms associated with these conditions by modulating dopamine levels and restoring the balance in neural signaling.
Pharmaceutical companies utilize advanced synthesis and purification techniques to produce high-quality dopamine antagonists for use as active ingredients in various medications. These APIs undergo stringent quality control measures to ensure their safety, efficacy, and compliance with regulatory standards.
In conclusion, dopamine antagonists constitute an important subcategory of pharmaceutical APIs, offering valuable therapeutic benefits for psychiatric disorders, nausea, vomiting, and movement disorders. Their ability to selectively block dopamine receptors makes them indispensable in modern medicine, enabling improved patient outcomes and quality of life.
Alizapride (Dopamine antagonists), classified under Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
Alizapride API manufacturers & distributors
Compare qualified Alizapride API suppliers worldwide. We currently have 1 companies offering Alizapride API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| ICROM | Producer | Italy | Italy | CoA, GMP, USDMF | 19 products |
When sending a request, specify which Alizapride API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Alizapride API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
